Weekly update|Companies|Recruiting|Promote|Post a job

AmbAgon Therapeutics

Founded: 2020

Location: South SF, CA

Employee range: 11 - 50

Clinical stage: RD

Therapy area: Oncology

Drug types: ONC

Lead product: Undisclosed

Product link: https://www.ambagontx.com/platform-pipeline/

Funding: $85M A Jan 2022

Investors: Nextech Invest, RA Capital Management, Droia Ventures, Inkef Capital, AbbVie Ventures, MRL Ventures Fund, Mission BioCapital, Surveyor Capital

ambagontx.com

linkedin.com

job board

Short description:

Small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins

Drug notes:

6 additional undisclosed programs RD oncology

Long description:

Ambagon Therapeutics is enhancing the activity of tumor suppressors by creating cancer molecule therapeutics. 14-3-3 proteins are adaptor proteins that play a key role in a large number of disease-related pathways, but are intrinsically disordered, making it hard to design small molecule binders. However, these disordered regions become ordered when 14-3-3 binds other “client” protein interactors. Different clients create structurally unique pockets on 14-3-3 enabling Ambagon to develop small molecules that can stabilize specific 14-3–3:client interactions. Ambagon has built an extensive database of 14-3-3:client protein structures to quickly identify the most promising candidates for screening. Amabagon now has five programs in early discovery and expects one to reach development by 2023.

Jobs:

Main

Contact: recruit@workinbiotech.com